GSK plc announced promising results from its BEHOLD-1 clinical trial for mocertatug rezetecan, reporting a 62% response rate in platinum-resistant ovarian cancer and 67% in advanced endometrial cancer. This filing is significant as it supports the launch of five phase III trials in 2026.